Partenariat

Articles

• Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals
  3 February, by Emmanuelle BETTENDORF

  We are delighted to announce we have entered into a Material Transfer and Evaluation Agreement with OliX Pharmaceuticals, a leading developer of RNAi therapeutics, to initiate a collaboration focused on siRNA delivery for central nervous system (CNS) disorders.
  “We are extremely pleased to partner with OliX. This collaboration underscores Vect-Horus’ leadership in BBB technology and its commitment to advancing oligonucleotide therapeutics in CNS diseases through strategic partnerships with (…)

• Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics
  1 November 2023, by Emmanuelle BETTENDORF

  Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S. This agreement provides Novo Nordisk with worldwide, exclusive license to use Vect-Horus platform technology ”VECTrans”; for delivery of cargos directed against specified targets . Novo Nordisk has an option to add additional targets to the (…)

• Vect-Horus announces Collaboration and Option Agreement with ASTELLAS Pharma
  4 June 2019, by Jonathan NOWAK

  Vect-Horus announced today the signing of the Research Collaboration and Option Agreement (the “Agreement”) with Astellas Pharma Inc., a Japan based pharmaceutical company (“Astellas”). Vect-Horus will use its proprietary technology VECTrans® to transport Astellas’ antibody to the brain for the treatment of CNS diseases.

• Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
  30 January 2024, by Emmanuelle BETTENDORF

  Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). The agreement provides Ionis with a worldwide, exclusive license for a specified number of targets using Vect-Horus’ platform technology ”VECTrans” for systemic delivery of RNA-targeted therapeutics that (…)

• Vect-Horus announces agreement with Johnson&Johnson Innovation
  18 January 2019, by Jonathan NOWAK

  Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

• Vect-Horus further strengthens leadership with appointment of strategy and finance executive Jérôme Berger to its Board of Directors
  3 February 2025, by Emmanuelle BETTENDORF

  We are excited that Jerome Berger is joining our Board of Directors!
  Jerome brings vast expertise in strategy, finance, and venture capital in the technology and life sciences sectors, which will be invaluable as Vect-Horus accelerates its growth and development.
  “Jerome’s unparalleled experience in strategy, venture capital and global financing, coupled with his strong background in digital health and life sciences, will be invaluable in supporting the development of Vect-Horus as we (…)

• Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases
  28 January 2019, by Jonathan NOWAK

  The partnership will develop new molecules for the treatment of brain diseases
  Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific collaboration agreement with Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM). The financial terms of the deal have not been disclosed.
  This agreement is part of Vect-Horus’ strategy to leverage (…)

• Vect-Horus announces the signing of a scientific collaboration agreement with SERVIER
  28 January 2019, by Jonathan NOWAK

  The two companies intend to enter in a collaboration agreement to develop new therapeutic molecules in the field of central nervous system (CNS) diseases
  VECT-HORUS, a biotechnology company that designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents, notably in the brain, is announcing today the signing of a scientific collaboration agreement with SERVIER. The companies did not disclose the financial terms of this agreement. This collaboration is part (…)

• Vect-Horus is a partner laureate of the ANR MALZ 2011 call for proposals
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2011 call for proposals and will be involved in the PREVENTAD project coordinated by the UMR7259 laboratory (Coordinator, Dr. Michel Khrestchatisky).
  This project received support (label) from the EUROBIOMED Biocluster.
  VECT-HORUS recruits to reinforce its in vitro BBB model platform.

• Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
  11 July 2025, by Emmanuelle BETTENDORF

  We are proud and excited to announce a new strategic research collaboration with Secarna Pharmaceuticals!
  The partnership will focus on developing RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS), combining our delivery technology platform, VECTrans®, with Secarna’s proprietary OligoCreator® oligonucleotide discovery platform.
  The combination of these two technologies will expand Secarna’s targeted (…)